Myriad Genetics Inc
NASDAQ:MYGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15
28.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Myriad Genetics Inc
Myriad Genetics Inc
Total Liabilities
Myriad Genetics Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Myriad Genetics Inc
NASDAQ:MYGN
|
Total Liabilities
$344.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
14%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$83.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$6.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$8.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
Myriad Genetics Inc
Glance View
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,400 full-time employees. The firm primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The firm discovers and commercializes genetic tests. The firm's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company’s wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc., Myriad Women’s Health, Inc, Myriad Genetics Espana SL, Myriad Genetics S.r.l., Myriad Genetics B.V. and Myriad Genetics GK.
See Also
What is Myriad Genetics Inc's Total Liabilities?
Total Liabilities
344.6m
USD
Based on the financial report for Sep 30, 2024, Myriad Genetics Inc's Total Liabilities amounts to 344.6m USD.
What is Myriad Genetics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
14%
Over the last year, the Total Liabilities growth was -26%. The average annual Total Liabilities growth rates for Myriad Genetics Inc have been -2% over the past three years , -8% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
